Media & Science Communication

Our PROX1 study was picked up by 12 news outlets in Europe, Asia and North America, placing it in the top 5% of all research outputs tracked by Altmetric. Link to Altmetric. 

In the “Reprogramming Stars” interview series, Moritz Mall talks about engineering cell fates and preventing disease by repressing unwanted plasticity. Link to the article. 

The Transmitter reports on our MYT1L study; Moritz Mall explains why lifelong MYT1L activity may widen the window for treatment. Link to audio and article. 

Our MYT1L study was picked up by 42 news outlets worldwide, placing it in the top 5% of all research outputs tracked by Altmetric. Coverage ranged from Healthline and MedPage Today to New York Post, Daily Mail and The Sun. Link to Altmetric. 

In a Behind the Paper post, first author Bettina Weigel tells the story of our MYT1L study – from “confused” neuron identity to a possible treatment with an approved drug. Link to “Behind the paper” article. 

Nature Reviews Neuroscience highlighted our discovery that MYT1L keeps neurons in shape by silencing all other cell fates. Link to the article. 

Our 2017 Nature paper was picked up by 6 news outlets in Europe, North America and Asia, placing it in the top 5% of all research outputs tracked by Altmetric. Coverage included a feature in Spektrum der Wissenschaft and a research highlight on Nature Asia. Link to Altmetric.